Voyager Therapeutics Inc (VYGR) Insider Bernard Ravina Sells 3,630 Shares

Voyager Therapeutics Inc (NASDAQ:VYGR) insider Bernard Ravina sold 3,630 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total transaction of $59,532.00. Following the transaction, the insider now directly owns 7,353 shares in the company, valued at $120,589.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Bernard Ravina also recently made the following trade(s):

  • On Monday, December 11th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.63, for a total transaction of $74,828.70.
  • On Friday, November 10th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.26, for a total transaction of $72,797.40.

Voyager Therapeutics Inc (VYGR) traded up $0.11 during midday trading on Friday, hitting $18.38. 212,557 shares of the stock were exchanged, compared to its average volume of 345,199. Voyager Therapeutics Inc has a 1 year low of $8.10 and a 1 year high of $25.99. The company has a market capitalization of $574.58, a P/E ratio of -6.47 and a beta of 3.89.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its stake in shares of Voyager Therapeutics by 57.7% during the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after purchasing an additional 4,343 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Voyager Therapeutics during the third quarter valued at approximately $270,000. Oppenheimer & Co. Inc. bought a new position in shares of Voyager Therapeutics during the second quarter valued at approximately $143,000. Rhumbline Advisers boosted its stake in shares of Voyager Therapeutics by 34.7% during the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after purchasing an additional 4,144 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Voyager Therapeutics by 8.9% during the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after purchasing an additional 1,399 shares in the last quarter. Hedge funds and other institutional investors own 35.97% of the company’s stock.

A number of equities analysts have recently commented on VYGR shares. Stifel Nicolaus reaffirmed a “buy” rating and set a $31.00 target price (up from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Canaccord Genuity started coverage on shares of Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 target price on the stock. Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. Raymond James Financial started coverage on shares of Voyager Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Cowen reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. Voyager Therapeutics currently has a consensus rating of “Buy” and an average target price of $26.90.

COPYRIGHT VIOLATION WARNING: “Voyager Therapeutics Inc (VYGR) Insider Bernard Ravina Sells 3,630 Shares” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/voyager-therapeutics-inc-vygr-insider-bernard-ravina-sells-3630-shares.html.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply